Eprotirome is a thyromimetic drug that has been investigated for the treatment of dyslipidemia. A Phase III trial in humans was discontinued after the drug was found to have negative effects on cartilage in dogs.[1][2]

Eprotirome
Identifiers
  • 2-({3,5-Dibromo-4-[4-hydroxy-3-(propan-2-yl)phenoxy]phenyl}carbamoyl)acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H17Br2N2O5
Molar mass501.151 g·mol−1
3D model (JSmol)
  • CC(C)C1=C(C=CC(=C1)OC2=C(C=C(C=C2Br)NC(=O)CC(=O)O)Br)O
  • InChI=1S/C18H17Br2NO5/c1-9(2)12-7-11(3-4-15(12)22)26-18-13(19)5-10(6-14(18)20)21-16(23)8-17(24)25/h3-7,9,22H,8H2,1-2H3,(H,21,23)(H,24,25)
  • Key:VPCSYAVXDAUHLT-UHFFFAOYSA-N

References

edit
  1. ^ Saponaro, Federica; Sestito, Simona; Runfola, Massimiliano; Rapposelli, Simona; Chiellini, Grazia (2020). "Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders". Frontiers in Medicine. 7: 331. doi:10.3389/fmed.2020.00331. ISSN 2296-858X. PMC 7363807. PMID 32733906.
  2. ^ Unnikrishnan, A. G.; Baruah, Manash; Kalra, Sanjay (December 2012). "Thyromimetics: What does the future hold?". Indian Journal of Endocrinology and Metabolism. 16 (Suppl 2): S159–S161. doi:10.4103/2230-8210.104029. ISSN 2230-8210. PMC 3603016. PMID 23565368.